VBLT News and Press, Vascular Biogenics Ltd. From 04/06/20

TEL AVIV, Israel, April 06, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), announced today that it has reached a milestone event under its collaborative agreement with a world-leading European animal health company, evaluating use of VB-201 for veterinary applications. Upon rea...

TEL AVIV, Israel, April 02, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced that following the positive interim analysis in the OVAL study, its Japanese licensee NanoCarrier Co., Ltd. (TSE Mothers: 4571), intends to extend the ongoing global Phase 3 OVAL clinic...

Vascular Biogenics (VBLT), which operates as VBL Therapeutics, is a clinical stage pharmaceutical company focused on cancer therapies. Its lead program, VB-111 for glioblastoma (brain cancer), failed to produce positive Phase 3 results in 2018, resulting in a collapse of the company's stock pr...

TherapeuticsMD Provides Business Updates, Suspends Guidance Due to COVID 19 TherapeuticsMD ( TXMD ) announced important updates about its business operations including introducing cost reduction initiatives. The company also stated that it has decided to suspend its guidance for FY 2020....

Granite Point Mortgage Trust (NYSE: GPMT ) +104%  on suspending Q1 dividend in move to conserve cash. More news on: Granite Point Mortgage Trust Inc., MFA Financial, Inc., Wanda Sports Group Company Limited, Stocks on the move, , Read more ...

VBL Therapeutics (NASDAQ: VBLT ) announces positive interim results from a Phase 3 clinical trial, OVAL , evaluating VB-111 in patients with platinum-resistant ovarian cancer. More news on: Vascular Biogenics Ltd., Healthcare stocks news, Stocks on the move, Read more ...

OVAL independent Data Safety Monitoring Committee (DSMC) reviewed un-blinded data and determined that the study has met the interim pre-specified criterion, of an absolute percentage advantage of 10% or higher in CA-125 response in the VB-111 treated arm compared to control. The DSMC recom...

OVAL independent Data Safety Monitoring Committee (DSMC) reviewed un-blinded data and determined that the study has met the interim pre-specified criterion, of an absolute percentage advantage of 10% or higher in CA-125 response in the VB-111 treated arm compared to control. The DSMC reco...

Vascular Biogenics Ltd. (VBLT) Q4 2019 Results Earnings Conference Call March 19, 2020 08:30 AM ET Company Participants Michael Wood - IR, LifeSci Advisors Dror Harats - CEO Amos Ron - CFO Conference Call Participants Kevin DeGeeter - Oppenheimer Sam Slutsky - LifSci ...

Vascular Biogenics (NASDAQ: VBLT ): FY GAAP EPS of -$0.54. More news on: Vascular Biogenics Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...